These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Analysis of potential microRNA biomarkers for multiple sclerosis. Al-Temaimi R; Alshammari N; Alroughani R Exp Mol Pathol; 2024 Jun; 137():104903. PubMed ID: 38772208 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta. Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province. Jafarinia M; Sadeghi E; Alsahebfosoul F; Etemadifar M; Jahanbani-Ardakani H Int J Neurosci; 2020 May; 130(5):493-498. PubMed ID: 31795798 [No Abstract] [Full Text] [Related]
10. MicroRNAs Correlate with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in a Chinese Population. Chen J; Zhu J; Wang Z; Yao X; Wu X; Liu F; Zheng W; Li Z; Lin A Med Sci Monit; 2017 May; 23():2565-2583. PubMed ID: 28550707 [TBL] [Abstract][Full Text] [Related]
11. Apoptotic protease activating factor-1 gene and MicroRNA-484: A possible interplay in relapsing remitting multiple sclerosis. Mohamed DAW; Selim HM; Elmazny A; Genena A; Nabil MM Mult Scler Relat Disord; 2022 Feb; 58():103502. PubMed ID: 35030371 [TBL] [Abstract][Full Text] [Related]
12. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study. Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141 [No Abstract] [Full Text] [Related]
13. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients. Arisi I; Malimpensa L; Manzini V; Brandi R; Gosetti di Sturmeck T; D'Amelio C; Crisafulli S; Ferrazzano G; Belvisi D; Malerba F; Florio R; Pascale E; Soreq H; Salvetti M; Cattaneo A; D'Onofrio M; Conte A Front Immunol; 2023; 14():1234869. PubMed ID: 38152407 [TBL] [Abstract][Full Text] [Related]
14. Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis. Agostini S; Mancuso R; Citterio LA; Caputo D; Oreni L; Nuzzi R; Pasanisi MB; Rovaris M; Clerici M Neurobiol Dis; 2024 Oct; 200():106648. PubMed ID: 39181188 [TBL] [Abstract][Full Text] [Related]
15. Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity. Tavakolpour V; Shokri G; Naser Moghadasi A; Mozafari Nahavandi P; Hashemi M; Kouhkan F J Neuroimmunol; 2018 Dec; 325():79-86. PubMed ID: 30316680 [TBL] [Abstract][Full Text] [Related]